Skip to main content

Advertisement

Table 3 Disease activity (measured by the DAS28) and EULAR-disease activity classification percentages during one infusion interval

From: Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

  Prior to infusion 50% of the infusioninterval 75% of the infusioninterval 100% of the infusioninterval
Mean DAS28 (± SD) 3.3 (± 1.1) 3.0 (± 1.0) 3.4 (± 1.1) 3.4 (± 1.1)
Patients in remission (n, %) 7 (26%) 10 (37%) 6 (22%) 8 (30%)
Patients with low disease activity (n, %) 6 (22%) 6 (22%) 6 (22%) 3 (11%)
Patients with moderate disease activity (n, %) 11 (41%) 11 (41%) 14 (52%) 15 (56%)
Patients with high disease activity (n, %) 3 (11%) 0 (0%) 1 (4%) 1 (4%)